Pharmaceutical company ANI Pharmaceuticals agreed to acquire Novitium Pharma, a New Jersey-based pharmaceutical company with development, manufacturing, and commercialization capabilities, for $210m. "Strengthening our well-established Generics business with enhanced development capabilities and increased focus on niche opportunities is a key pillar of ANI’s growth strategy. The acquisition of Novitium aligns with this strategy, adding a best-in-class R&D engine that delivers sustainable growth through new product launches and offering upside through niche 505(b)(2) opportunities," Nikhil Lalwani, ANI Pharmaceuticals President and CEO. On November 10, 2021, FTC approved the deal with conditions.